Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the safety and effectiveness of the IOPtiMate (OT-135P) in Laser Assisted Non-Penetrating Glaucoma surgery in Open-Angle and Pseudoexfoliative Glaucoma patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma

NCT01383525

Glaucoma

COMPLETED NA

Titanium-Sapphire Laser Trabeculoplasty in Glaucoma: A Randomized Study Comparing Titanium-Sapphire With Argon Laser Trabeculoplasty in Open-Angle Glaucoma Patients

NCT00470964

Glaucoma, Open-Angle

COMPLETED NA

Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma

NCT01956942

Open Angle Glaucoma

COMPLETED NA

Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents

NCT01252862

Subjects With Primary Open-angle Glaucoma (POAG)

COMPLETED PHASE4

Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents

NCT01456390

Open-Angle Glaucoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma Pseudo-Exfoliative Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IOPtiMate

patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system

Group Type EXPERIMENTAL

Laser Assisted Non-penetrating glaucoma surgery

Intervention Type DEVICE

A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laser Assisted Non-penetrating glaucoma surgery

A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient must be 18 years of age or older.
2. Patient must have primary open angle glaucoma or pseudo-exfoliative glaucoma in the study eye; diagnosis is based on glaucomatous optic neuropathy, Shaffer angle of +2 and visual field defect attributed to glaucoma (at least two consecutive abnormal visual field test results, defined as a pattern SD (PSD) outside the 95% normal confidence limits and/or glaucoma Hemifield Test (Carl Zeiss Meditec, Inc.).
3. Eye to be treated must be phakic or pseudophakic eye with no ocular disorder or ocular diseases but cataract, and no prior surgical intervention in study eye but cataract surgery with clear corneal incision and trabeculoplasty performed \> 3 months ago.
4. Patient is indicated for filtration surgery.
5. Presence of ocular hypertension, defined as an intraocular corrected pressure (IOP) ≥ 21 mm Hg in the study eye, while on maximal tolerated medications . This IOP level of above or equal 21 mmHg must be verified and recorded in the most recent 2 consecutive measurements (but not taken on the same day) prior to operation.
6. Best corrected visual acuity (BCVA) better than 20/200 in the fellow eye.
7. Optic neuropathy is attributed exclusively to glaucoma.
8. Patient or legal guardian agrees to sign written informed consent prior to study participation.
9. Patient is able and willing to complete post-operative follow-up requirements.

Exclusion Criteria

1. Patient has previously undergone a non-penetrating glaucoma surgery with the IOPtima CO2 Laser System in fellow eye.
2. Diagnosis of glaucoma other than primary open angle glaucoma or pseudo-exfoliative glaucoma.
3. History of previous intraocular surgery in the study eye; referring to but not limited to glaucoma filtering surgery (penetrating and non-penetrating), laser gonioplasty, corneal transplant, and history of any other laser ocular procedures except for laser trabeculoplasty surgery.
4. Laser trabeculoplasty surgery within the last three months in the study eye.
5. Study eye is aphakic.
6. Patients with previous cataract extraction with scleral tunnel and or conjunctival incision in the study eye.
7. Proliferative or severe non-proliferative retinopathy in either eye.
8. Eyes with (dilated) pupil diameter of less than 2 mm in the study eye.
9. Discernable congenital anomaly of the anterior chamber angle in the study eye.
10. Patients with neuropathy other than glaucoma in the study eye.
11. Patient with RVO (retinal vein occlusion) in the study eye.
12. Patient with RAO (retinal artery occlusion) in the study eye.
13. History of prior vitrectomy or Vitreous Hemorrhage (VH) in the study eye.
14. Patient with media opacification which may interfere with optic nerve evaluation in the study eye.
15. Patient with a history of severe eye trauma in the study eye
16. Patient with ocular malformations such as microphthalmia in the study eye.
17. Patient with concurrent inflammatory / infective eye disorder (e.g. episcleritis, scleritis) in the study eye
18. Patient with any sign of past or present uveitis (anterior / posterior)
19. Patient with known allergy to the study medications.
20. Patient with severe systemic disease or disabling conditions such as: chronic renal failure requiring dialysis, severe and disenabling neurological disease, and post organ transplants.
21. Patient participating in another clinical trial or participation in another clinical trial is \< 3 months.
22. Patient is pregnant or breast feeding. Women of child bearing age will submit a urine sample result for β-HCG (Pregnancy test) within 2 weeks of surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No